Text Size

Study Evaluating Anxiety and Depression in Patients With Psoriatic Arthritis

This study has been completed.
Sponsor:
Information provided by:
Wyeth is now a wholly owned subsidiary of Pfizer
ClinicalTrials.gov Identifier:
NCT00884468
First received: April 16, 2009
Last updated: May 26, 2009
Last verified: May 2009
History of Changes
  Purpose

This is an epidemiological non-interventional study assessing the prevalence of anxiety and/or depression disorders in patients suffering from Psoriatic Arthritis (PsA) in Spain.


Condition
Psoriatic Arthritis

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Cross-Sectional
Official Title: Anxiety and Depression in Patients With Psoriatic Arthritis: Prevalence and Characteristics

Resource links provided by NLM:

MedlinePlus related topics: Anxiety Depression
U.S. FDA Resources

Further study details as provided by Wyeth is now a wholly owned subsidiary of Pfizer:

Primary Outcome Measures:
  • Prevalence of anxiety and/or depression disorders in patients suffering from PsA in Spain as measured by the Hospital Anxiety and Depression Scale (HAD) [ Time Frame: 12 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • To assess the relation between the PsA severity and the presence of anxiety and/or depression disorders in patients suffering from PsA in Spain. [ Time Frame: 12 months ] [ Designated as safety issue: No ]

Enrollment: 384
Study Start Date: May 2008
Study Completion Date: December 2008
Primary Completion Date: December 2008 (Final data collection date for primary outcome measure)
Groups/Cohorts
1
Patients with PsA that fulfill the eligibility criteria of the study

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

Patients with PsA from outpatient's surgery or primary health care centres

Criteria

Inclusion criteria:

  • Patients both genders over 18 years old
  • Patients with PsA diagnosis

Exclusion criteria:

  • Patients with PsA that suffer from other rheumatologic diseases or non-concomitant rheumatologic diseases that the investigator considers not to be appropriate for the study.
  • Patients with any medical or physical condition (cognitive damage or difficulties for understanding) that create difficulties for reading and completing the questionnaires described in the protocol.
  • Patients that in the study period are taking part in another clinical trial.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00884468

Locations
Spain
Reus, Tarragona, Spain, 43201
Sponsors and Collaborators
Wyeth is now a wholly owned subsidiary of Pfizer
Investigators
Study Director: Medical Monitor Wyeth is now a wholly owned subsidiary of Pfizer
  More Information

No publications provided

Responsible Party: Wyeth (Registry Contact: Clinical Trial Registry Specialist), Wyeth
ClinicalTrials.gov Identifier: NCT00884468     History of Changes
Other Study ID Numbers: 0881A5-4468
Study First Received: April 16, 2009
Last Updated: May 26, 2009
Health Authority: Spain: Comité Ético de Investigación Clínica

Keywords provided by Wyeth is now a wholly owned subsidiary of Pfizer:
Anxiety and depression in patients with psoriatic arthritis

Additional relevant MeSH terms:
Arthritis
Arthritis, Psoriatic
Anxiety Disorders
Depression
Depressive Disorder
Mental Disorders
Joint Diseases
Musculoskeletal Diseases
Spondylarthropathies
 Spondylarthritis
Spondylitis
Spinal Diseases
Bone Diseases
Psoriasis
Skin Diseases, Papulosquamous
Skin Diseases
Behavioral Symptoms
Mood Disorders

ClinicalTrials.gov processed this record on June 18, 2013